New pyrazolobenzopyran derivatives show antioxidant and COX inhibitory potential

In a development that could reshape how medicinal chemists approach inflammation treatment, a team of Mexican researchers has designed and synthesized a family of hybrid molecules that merge coumarins—the fragrant compounds behind the sweet smell of newly cut hay and vanilla—with pyrazoles, the nitrogen-rich ring at the heart of blockbuster anti-inflammatory drugs like celecoxib. The new coumarin-pyrazole compounds, described in the journal Results in Chemistry, displayed meaningful antioxidant activity in laboratory tests and showed promising signals as selective inhibitors of cyclooxygenase-2, the enzyme targeted by modern painkillers, based on sophisticated computational modeling.

The work addresses a long-standing problem in pharmacology. Nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen relieve pain by blocking cyclooxygenase enzymes, but because they inhibit both COX-1 and COX-2, they carry well-known gastrointestinal and cardiovascular side effects. COX-2 is the inflammation-induced isoform of the enzyme, while COX-1 is the constitutive version that protects the stomach lining. Selective COX-2 inhibitors, known as coxibs, were developed to spare COX-1 and reduce side effects, but the search for safer, more effective scaffolds continues. Pyrazoles—five-membered aromatic rings containing two adjacent nitrogen atoms—have emerged as privileged structures in this hunt, appearing in celecoxib and in numerous experimental antimicrobial, antiviral, antimalarial, and even anticancer agents reported against breast adenocarcinoma and lung cancer cell lines.

Coumarins, meanwhile, are naturally occurring benzopyrone compounds found in plants, prized for antioxidant and antiproliferative properties. Chemists have long been intrigued by the possibility of fusing the two frameworks into single molecules, known as coumarin-pyrazoles, hoping to combine the biological virtues of both. Prior work by Grover and colleagues had already produced a set of 19 coumarin-pyrazole derivatives, one of which behaved as a selective COX-2 inhibitor. Yet the structure-activity relationships governing COX-2 selectivity in these hybrids remained poorly understood, and their antioxidant potential had never been systematically examined.

The research team, led by Cesar Alonso Villa-Martínez and Francisco Javier Martínez-Martínez, took a rational design approach grounded in structural biology. They began by examining published crystal structures of COX-2 bound to celecoxib and to the selective inhibitor SC-558, retrieved from the Protein Data Bank. A key observation emerged: both drugs anchor themselves in the enzyme’s catalytic site through hydrogen bonds with the residue Arg513, while surrounding hydrophobic residues—Leu352, Tyr355, Val349, Ala527, and Val523—cradle the bulky trifluoromethyl groups characteristic of coxibs. The team reasoned that enlarging the coumarin-pyrazole scaffold, particularly by replacing a methyl group with a full phenyl ring, might improve fit and potency within COX-2’s roomy, hydrophobic side pocket.

To fine-tune the molecules’ properties, the chemists turned to the Craig plot, a classic medicinal chemistry tool that maps substituents by hydrophobicity and electronic character. They deliberately selected substituents sharing similar electronic signatures but spanning a hydrophobicity range: a hydroxyl group and a diethylamino group, alongside methoxy and unsubstituted versions. This strategy let them isolate the effect of lipophilicity while holding electronic features roughly constant—an elegant way to dissect what drives biological activity.

The synthesis itself relied on chemistry that is refreshingly accessible compared with metal-catalyzed routes demanding harsh conditions. The team condensed phenylhydrazine with coumarin aldehyde precursors to form hydrazones, then cyclized these intermediates using copper acetate catalysis in ethanol or ethanol-tetrahydrofuran mixtures under reflux. Eight novel compounds resulted—four bearing a methyl group at the reactive position and four bearing a phenyl ring—each further diversified with hydrogen, hydroxyl, methoxy, or diethylamino substituents at the seven-position of the coumarin core. Yields ranged from 38 to 58 percent, with products isolated as crystalline solids whose structures were confirmed by nuclear magnetic resonance spectroscopy, infrared spectroscopy, and high-resolution mass spectrometry.

One compound, the diethylamino-substituted methyl derivative labeled 5b, yielded crystals suitable for single-crystal X-ray diffraction, giving the researchers an atom-by-atom view of the molecular architecture. The analysis, performed with molybdenum radiation on a Bruker diffractometer, revealed a triclinic crystal system in which the three fused rings sit coplanar while the pendant phenyl ring twists dramatically out of plane by nearly 73 degrees. This conformation enables an intramolecular carbon-hydrogen interaction with the phenyl ring’s pi-electron cloud, and in the solid state, molecules pair into dimers held together by hydrogen bonds between pyrazole hydrogens and pyrone carbonyls. The dimers then thread into one-dimensional chains through additional carbon-hydrogen to pi-ring contacts—a supramolecular arrangement the authors note is typical of coumarin systems and sensitive to substituent effects.

On the biological front, the compounds were subjected to the DPPH radical scavenging assay, a standard colorimetric test in which the deep purple DPPH radical loses absorbance at 517 nanometers as it is neutralized by antioxidants. Measured in quintuplicate against ascorbic acid as a positive control and 4-methylumbelliferone as a structural reference, the results were striking. Every synthesized coumarin-pyrazole outperformed the coumarin reference compound, which managed only about 38 percent scavenging. The standout was compound 6a—the phenyl-substituted, unsubstituted coumarin variant—which neutralized roughly 70 percent of the radicals, approaching half the performance of pure ascorbic acid at the same concentration. The structure-activity trend was clear across both series: bulkier, more hydrophobic substituents at the seven-position enhanced radical scavenging, following the order diethylamino greater than hydroxyl greater than hydrogen.

To probe anti-inflammatory potential without immediate animal or cell testing, the researchers deployed molecular docking calculations using AutoDock Vina. Crucially, they validated their computational protocol by reproducing the experimentally known binding poses of celecoxib in both COX-2 and COX-1 crystal structures, and by docking two additional confirmed selective inhibitors before evaluating their own compounds. Docking was performed against multiple crystal conformations of each enzyme—structures bound to naproxen, meloxicam, and ibuprofen for COX-2, and several additional COX-1 structures—to ensure conclusions were not artifacts of a single protein shape. Rather than relying solely on binding energy scores, the team focused on whether their compounds replicated the key interactions with residues known to matter for selective inhibition, including Arg513, His90, Ala527, and the hydrophobic pocket residues.

Supporting the docking analysis, the team ran quantum chemical calculations at a high theoretical level, optimizing molecular geometries with the PM6 semiempirical method followed by single-point calculations using the M06-2X density functional with a 6-311+G(2d,p) basis set. From these they derived frontier molecular orbital energies, molecular electrostatic potential maps, ionization potential surfaces, and a battery of conceptual DFT descriptors—chemical hardness, softness, electronic chemical potential, and electrophilicity index—calculated through finite-difference approximations of neutral, cationic, and anionic species. These descriptors help rationalize how electron density is distributed across each molecule and how readily each compound might donate electrons, the fundamental chemistry underlying antioxidant behavior.

The convergence of experimental and computational evidence points to the phenyl-bearing derivatives as the most promising leads. Their enhanced radical scavenging, larger molecular footprint, and predicted compatibility with COX-2’s hydrophobic side pocket suggest that the hybrid strategy is working: the coumarin contributes antioxidant electron-rich character while the expanded pyrazole-coumarin framework mimics the size and shape requirements of selective coxib binding. The authors emphasize that the relationship between structural variation and COX-2 selectivity in this chemical family has now been illuminated in a way it had not been before.

Caveats remain substantial. DPPH assays measure radical neutralization in a test tube, not in living systems, and docking scores are hypotheses rather than proof of enzyme inhibition. Clinical development from such early-stage chemistry typically spans a decade or more, with attrition rates exceeding 90 percent. Still, the study exemplifies a modern, multi-pronged workflow—rational design informed by crystallography, accessible synthesis, rigorous structural characterization, quantum chemical analysis, and validated computational screening—that is accelerating the early stages of drug discovery. As inflammation remains central to ailments from arthritis to neurodegeneration, molecules that marry the antioxidant pedigree of natural coumarins with the anti-inflammatory pedigree of pyrazole drugs represent exactly the kind of creative molecular hybridization the field is hungry for. The next step will be experimental confirmation of COX-2 inhibition in enzymatic assays, a test these computationally promising candidates now seem poised to face.